WG
XLRN

Winton Group’s Acceleron Pharma XLRN Stock Holding History

Winton Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,274
Closed -$1.42M – 1549
2021
Q3 		$1.42M Sell
8,274
-115
-1% -$15K 0.08% 332
2021
Q2 		$1.05M Sell
8,389
-2,114
-20% -$267K 0.06% 502
2021
Q1 		$1.42M Buy
10,503
+4,062
+63% +$525K 0.08% 277
2020
Q4 		$824K Sell
6,441
-11,277
-64% -$1.32M 0.06% 512
2020
Q3 		$1.99M Sell
17,718
-14,019
-44% -$1.4M 0.06% 529
2020
Q2 		$3.02M Buy
31,737
+15,138
+91% +$1.46M 0.08% 453
2020
Q1 		$1.49M Sell
16,599
-52
-0.3% -$4.04K 0.04% 659
2019
Q4 		$883K Buy
+16,651
New +$759K 0.01% 1099

Winton Group's XLRN Position: Q4 2021 in Review

Winton Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 8,274 shares — an estimated $1.42M sold.

Winton Group first reported a position in XLRN in Q4 2019 and held it in 8 quarters. The position peaked at $3.02M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Winton Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 8,274 Acceleron Pharma shares in Q4 2021, an estimated $1.42M.
  • Winton Group first reported a position in Acceleron Pharma in Q4 2019 and held it in 8 quarters.
  • Winton Group's Acceleron Pharma position peaked at $3.02M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.